02410.HK
TYK Medicines, Inc
HKSE · Healthcare · Drug Manufacturers - General · CN
HKD 3.09
−2.22%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 107.0K | — | 44.2M |
| Cost of Revenue | — | 24.4M | 93.0K | 27.7M | 24.2M |
| Gross Profit | — | (24.4M) | 14.0K | (27.7M) | 20.0M |
| Operating Expenses | |||||
| R&D Expense | 250.2M | 221.6M | 235.4M | 249.3M | 229.8M |
| SG&A Expense | 102.3M | 78.5M | 108.3M | 59.3M | 11.3M |
| General & Admin Expense | 102.3M | 78.5M | 108.3M | 59.3M | 11.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | (10.2M) | (27.0M) | — | 13.8M |
| Total Operating Expenses | 352.5M | 289.8M | 316.8M | 308.6M | 254.8M |
| Cost and Expenses | 352.5M | 314.2M | 316.9M | 308.6M | 279.0M |
| Operating Income (EBIT) | (352.5M) | (314.2M) | (316.8M) | (306.8M) | (234.8M) |
| Non-Operating | |||||
| Interest Income | — | 2.7M | 2.0M | 700.0K | 2.0M |
| Interest Expense | — | 14.5M | 12.6M | 8.7M | 3.3M |
| Net Interest Income | (17.8M) | (11.9M) | (10.6M) | (8.0M) | (1.2M) |
| Other Non-Op Income/Expense | 133.7M | 16.1M | (71.1M) | (74.6M) | (77.0M) |
| Non-Operating Income (excl Interest) | — | — | 58.6M | — | 73.8M |
| EBT (Pre-Tax Income) | (218.8M) | (298.1M) | (387.9M) | (383.2M) | (311.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (212.5M) | (292.0M) | (387.0M) | (382.4M) | (311.0M) |
| Earnings from Cont. Ops | (218.8M) | (298.1M) | (387.9M) | (383.2M) | (311.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (212.5M) | (292.0M) | (387.0M) | (382.4M) | (311.0M) |
| Per Share | |||||
| Basic EPS | (HK$0.56) | (HK$0.78) | (HK$1.15) | (HK$1.03) | (HK$0.84) |
| Diluted EPS | (HK$0.56) | (HK$0.78) | (HK$1.15) | (HK$1.03) | (HK$0.84) |
| Revenue Per Share | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.00 | HK$0.12 |
| Shares | |||||
| Basic Shares Outstanding | 378.6M | 374.5M | 337.6M | 370.8M | 370.8M |
| Diluted Shares Outstanding | 378.6M | 374.5M | 337.6M | 370.8M | 370.8M |
| Profitability Metrics | |||||
| EBITDA | (329.8M) | (289.2M) | (346.0M) | (346.8M) | (292.2M) |
| D&A | 22.7M | 25.0M | 29.3M | 27.6M | 16.3M |
| EBIT | (352.5M) | (314.2M) | (375.4M) | (306.8M) | (308.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026